A recent patient discussion highlighted important questions about how to approach HCV infection in renal disease.
Despite the variety of highly effective, highly tolerable regimens available for treating HCV, strategies for patients with decompensated liver disease remain challenging.
In my practice, it is the patient with cirrhosis and genotype 3 HCV infection who causes me to pause and carefully consider the patient’s treatment options.
In this downloadable slideset, Mark S. Sulkowski, MD; Ira M. Jacobson, MD; and Nancy Reau, MD, FAASLD, AGAF, present evolving clinical data on the management of HCV infection in harder-to-treat patient populations, including patients with compensated or decompensated cirrhosis, renal impairment, genotype 3 HCV infection, and HIV coinfection.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.